Global Short Bowel Syndrome Market By Indication( Diarrhoea, Fatigue, Weight loss, Malnutrition, Others) By Diagnosis( Blood Tests, Computerized Tomography (CT) scan, Fecal Fat Tests, Upper Gastrointestinal (GI) Series, X-ray, Liver Biopsy, Others) By Treatment(Nutritional support(Oral rehydration, Parenteral nutrition, Vitamin and mineral supplements, Special Diet, Others) Medications(GLP-2, Glutamine, Growth Hormones, Others), Intestinal transplant surgery, Others)) By Application( Infants / Children, Adults) By End Users(Gastrointestinal Specialty Clinics, Hospitals, Others)By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022– 2030
Industry Trends
The medical literary definition of small bowel syndrome has changed throughout time.Although some medical sources seem to reserve the term "short bowel syndrome" for cases involving surgical resection of a portion of the small intestine. While others have stated that the disorder can be caused by any disease, injury, or condition that impairs or prevents the proper function of the small intestine, even if the bowel's length is unaffected. In the last few years, short bowel disease is becoming better managed, owing to increased awareness and the availability of epidemiological data and treatments. Currently long-term parenteral nutrition or an organ transplant are used to treat short bowel syndrome (SBS).As the former treatment's effect is unknown, the latter is tied to a shortage of organs.As a result, researchers working on the EU-funded INTENS project are attempting to design a more effective alternative. Moreover there is a growing demand for intravenous fluid supplementation to maintain normal hydration and urine output for the patients suffering from short bowel syndrome. Thus, to cater to this demand manufacturers in the short bowel syndrome market are advancing their efforts to address this need for patients suffering from problems such as dehydration, hyponatremia, and chronic renal failure. For instance, inJune 2021, VectivBio Holding AG announced the FDA approval for Apraglutide, a next-generation, long-acting GLP-2 analogue being developed for uncommon gastrointestinal (GI) illnesses. Thus such factors are leading to the growth of the short bowel syndrome market globally.
In terms of revenue, global short bowel syndrome market was valued at US$1.092.16Mn in 2021 growing at a CAGR of 24.6% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Short Bowel Syndrome Market Revenue & Forecast, (US$ Million), 2015 – 2030
Diagnosis Outlook
Based on diagnosis segment, the short bowl syndrome market is segmented into blood tests, computerized tomography (CT) scan, fecal fat tests, upper gastrointestinal (GI) series, X-ray, liver biopsy, others. The diagnosis of short bowel syndrome is undergoing huge advancements in terms of technology. The imaging techniques which are used to assess the patients with this syndrome provide a clear and effective diagnosis for further treatment.Computerized tomography (CT) imaging technique are widely being adopted due to its accuracy for diagnostic results. Computerized tomography uses X-rays and special computer software, this test creates two- and three-dimensional images of intestines.CT scans provide a different view of colon, pancreas and other organs, allowing to investigate details that conventional imaging studies might miss.This enables clinicians to check the health of the small intestine lining and find areas of stricture (narrowing) or irregular connections (fistulas) within the small bowels. Thus such advantageous factors of various imaging techniques has led to steady rise in the global short bowel syndrome market.
Treatment Outlook:
Based on the treatment outlook, the short bowel syndrome market is segmented into nutritional support, medication and intestinal transplant surgery. Nutritional support which is further segmented into oral rehydration, parenteral nutrition, vitamin and mineral supplements, special diet, and others accounted for the major chunk of the revenue in 2021. Nutritional diet has been prelevant treatment for short bowel treatment for a very long time. In some severe cases, medication absorption may be a major concern in patients with severe short bowel syndrome. Higher doses of medications lead to excess acid secretion in the stomach which could cause other intestinal problems. Thus to overcome this, in the last few years individuals with short bowel syndrome have been treated using a number of surgical methods.Surgery is typically performed as a last resort in patients who have failed to respond to other treatment choices.However, as surgical procedures have advanced, they are being regarded a first-line treatment in the future. Artificial lengthening of small intestine is gaining popularity to treat patients with short bowel syndrome. Furthermore pharmaceutical companies have on-going clinical trials for the treatment of short bowel syndrome which is boosting the global short bowel syndrome market.
End Users Outlook:
Based on the end users’ segment, the global short bowel syndrome market is segmented into gastrointestinal specialty clinics, hospitals and others. In the last decade there has been a steady rise in the number of patients with short bowel syndrome. Gastrointestinal specialty clinics are highly investing into advanced diagnostic instruments for better results and treatment of the syndrome. Moreover the short bowel syndrome requires a multidisciplinary approach for its treatment such as nutritional diets and proper medical assistance. Hospitals and healthcare organizations are introducing various intestinal rehabilitation programs and a dedicated gastroenterology team for faster and effective recovery. Thus the global short bowel syndrome market is expected to flourish in the forecast period 2022-2030.
Region Outlook:
Based on the regions, North America had the highest share in the short bowel syndrome market in the year 2021. Short bowel syndrome is one amongst the common syndrome in adults in United States and Canada. Healthcare organization and various government institutes are heavily investing into the treatment and medication therapies for short bowel syndrome. Moreover the healthcare institutions are providing financial assistance for diagnosis and treatments of the short bowel syndrome that has led to a growth of short bowel syndrome market in North America.
Competitive Landscape
The report provides both, qualitative and quantitative research of global short bowel syndrome market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global short bowel syndrome market are:
•9 Meters Biopharma, Inc.
•Adis International Ltd
•Ardelyx
•Emmaus Medical, Inc.
•Hanmi Pharm. Co. Ltd
• OxThera
•R&D Systems, Inc.
•Takeda Pharmaceuticals U.S.A., Inc.
•VectivBio AG
•Zealand Pharma A/S
•Other Market Participants
Global Short Bowel Syndrome Market:
By Indication
•Diarrhea
•Fatigue
•Weight loss
•Malnutrition
•Others
By Diagnosis
•Blood Tests
•Computerized Tomography (CT) scan
•Fecal fat tests
•Upper Gastrointestinal (GI) Series
•X-ray
•Liver Biopsy
•Others
By Treatment
•Nutritional support
oOral rehydration
oParenteral nutrition.
oVitamin and mineral supplements.
oSpecial Diet
oOthers
•Medications
oGLP-2
oGlutamine
oGrowth Hormones
oOthers
•Intestinal transplant surgery
•Others
By Application
•Infants / Children
•Adults
By End User
•Gastrointestinal Specialty Clinics
•Hospitals
•Others
By Region
•North America
oU.S.
oCanada
oMexico
oRest of North America
•Europe
oFrance
oThe UK
oSpain
oGermany
oItaly
oNordic Countries
Denmark
Finland
Iceland
Sweden
Norway
oBenelux Union
Belgium
The Netherlands
Luxembourg
oRest of Europe
•Asia Pacific
oChina
oJapan
oIndia
oNew Zealand
oAustralia
oSouth Korea
oSoutheast Asia
Indonesia
Thailand
Malaysia
Singapore
Rest of Southeast Asia
oRest of Asia Pacific
•Middle East & Africa
oSaudi Arabia
oUAE
oEgypt
oKuwait
oSouth Africa
oRest of Middle East & Africa
•Latin America
oBrazil
oArgentina
oRest of Latin America
Table of Contents 1. Market Scope 1.1. Market Segmentation 1.2. Years Considered 1.2.1. Historic Years: 2015 - 2020 1.2.2. Base Year: 2021 1.2.3. Forecast Years: 2022 – 2030 2. Key Target Audiences 3. Research Methodology 3.1. Primary Research 3.1.1. Research Questionnaire 3.1.2. Global Percentage Breakdown 3.1.3. Primary Interviews: Key Opinion Leaders (KOLs) 3.2. Secondary Research 3.2.1. Paid Databases 3.2.2. Secondary Sources 3.3. Market Size Estimates 3.3.1. Top-Down Approach 3.3.2. Bottom-Up Approach 3.4. Data Triangulation Methodology 3.5. Research Assumptions 4. Recommendations and Insights from AMI’s Perspective** 5. Holistic Overview of Short Bowel Syndrome Market 6. Market Synopsis: Short Bowel Syndrome Market 7. Short Bowel Syndrome Market Analysis: Qualitative Perspective 7.1. Introduction 7.1.1. Product Definition 7.1.2. Industry Development 7.2. Market Dynamics 7.2.1. Drivers 7.2.2. Restraints 7.2.3. Opportunities 7.2.4. Challenges 7.3. Trends in Short Bowel Syndrome Market 7.4. Market Determinants Radar Chart 7.5. Macro-Economic and Micro-Economic Indicators: Short Bowel Syndrome Market 7.6. Porter’s Five Force Analysis 7.7. Impact of Covid-19 on Short Bowel Syndrome Market 8. Global Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 8.1. Overview 8.1.1. Global Short Bowel Syndrome Market Revenue (US$ Mn) 8.2. Global Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 8.2.1. Diarrhea 8.2.1.1. Definition 8.2.1.2. Market Estimation and Penetration, 2015 - 2021 8.2.1.3. Market Forecast, 2022 – 2030 8.2.1.4. Compound Annual Growth Rate (CAGR) 8.2.1.5. Regional Bifurcation 8.2.1.5.1. North America 8.2.1.5.1.1. Market Estimation, 2015 - 2021 8.2.1.5.1.2. Market Forecast, 2022 – 2030 8.2.1.5.2. Europe 8.2.1.5.2.1. Market Estimation, 2015 - 2021 8.2.1.5.2.2. Market Forecast, 2022 – 2030 8.2.1.5.3. Asia Pacific 8.2.1.5.3.1. Market Estimation, 2015 - 2021 8.2.1.5.3.2. Market Forecast, 2022 – 2030 8.2.1.5.4. Middle East and Africa 8.2.1.5.4.1. Market Estimation, 2015 - 2021 8.2.1.5.4.2. Market Forecast, 2022 – 2030 8.2.1.5.5. Latin America 8.2.1.5.5.1. Market Estimation, 2015 - 2021 8.2.1.5.5.2. Market Forecast, 2022 – 2030 8.2.2. Fatigue 8.2.2.1. Definition 8.2.2.2. Market Estimation and Penetration, 2015 - 2021 8.2.2.3. Market Forecast, 2022 – 2030 8.2.2.4. Compound Annual Growth Rate (CAGR) 8.2.2.5. Regional Bifurcation 8.2.2.5.1. North America 8.2.2.5.1.1. Market Estimation, 2015 - 2021 8.2.2.5.1.2. Market Forecast, 2022 – 2030 8.2.2.5.2. Europe 8.2.2.5.2.1. Market Estimation, 2015 - 2021 8.2.2.5.2.2. Market Forecast, 2022 – 2030 8.2.2.5.3. Asia Pacific 8.2.2.5.3.1. Market Estimation, 2015 - 2021 8.2.2.5.3.2. Market Forecast, 2022 – 2030 8.2.2.5.4. Middle East and Africa 8.2.2.5.4.1. Market Estimation, 2015 - 2021 8.2.2.5.4.2. Market Forecast, 2022 – 2030 8.2.2.5.5. Latin America 8.2.2.5.5.1. Market Estimation, 2015 - 2021 8.2.2.5.5.2. Market Forecast, 2022 – 2030 8.2.3. Weight loss 8.2.3.1. Definition 8.2.3.2. Market Estimation and Penetration, 2015 - 2021 8.2.3.3. Market Forecast, 2022 – 2030 8.2.3.4. Compound Annual Growth Rate (CAGR) 8.2.3.5. Regional Bifurcation 8.2.3.5.1. North America 8.2.3.5.1.1. Market Estimation, 2015 - 2021 8.2.3.5.1.2. Market Forecast, 2022 – 2030 8.2.3.5.2. Europe 8.2.3.5.2.1. Market Estimation, 2015 - 2021 8.2.3.5.2.2. Market Forecast, 2022 – 2030 8.2.3.5.3. Asia Pacific 8.2.3.5.3.1. Market Estimation, 2015 - 2021 8.2.3.5.3.2. Market Forecast, 2022 – 2030 8.2.3.5.4. Middle East and Africa 8.2.3.5.4.1. Market Estimation, 2015 - 2021 8.2.3.5.4.2. Market Forecast, 2022 – 2030 8.2.3.5.5. Latin America 8.2.3.5.5.1. Market Estimation, 2015 - 2021 8.2.3.5.5.2. Market Forecast, 2022 – 2030 8.2.4. Malnutrition 8.2.4.1. Definition 8.2.4.2. Market Estimation and Penetration, 2015 - 2021 8.2.4.3. Market Forecast, 2022 – 2030 8.2.4.4. Compound Annual Growth Rate (CAGR) 8.2.4.5. Regional Bifurcation 8.2.4.5.1. North America 8.2.4.5.1.1. Market Estimation, 2015 - 2021 8.2.4.5.1.2. Market Forecast, 2022 – 2030 8.2.4.5.2. Europe 8.2.4.5.2.1. Market Estimation, 2015 - 2021 8.2.4.5.2.2. Market Forecast, 2022 – 2030 8.2.4.5.3. Asia Pacific 8.2.4.5.3.1. Market Estimation, 2015 - 2021 8.2.4.5.3.2. Market Forecast, 2022 – 2030 8.2.4.5.4. Middle East and Africa 8.2.4.5.4.1. Market Estimation, 2015 - 2021 8.2.4.5.4.2. Market Forecast, 2022 – 2030 8.2.4.5.5. Latin America 8.2.4.5.5.1. Market Estimation, 2015 - 2021 8.2.4.5.5.2. Market Forecast, 2022 – 2030 8.2.5. Others 8.2.5.1. Definition 8.2.5.2. Market Estimation and Penetration, 2015 - 2021 8.2.5.3. Market Forecast, 2022 – 2030 8.2.5.4. Compound Annual Growth Rate (CAGR) 8.2.5.5. Regional Bifurcation 8.2.5.5.1. North America 8.2.5.5.1.1. Market Estimation, 2015 - 2021 8.2.5.5.1.2. Market Forecast, 2022 – 2030 8.2.5.5.2. Europe 8.2.5.5.2.1. Market Estimation, 2015 - 2021 8.2.5.5.2.2. Market Forecast, 2022 – 2030 8.2.5.5.3. Asia Pacific 8.2.5.5.3.1. Market Estimation, 2015 - 2021 8.2.5.5.3.2. Market Forecast, 2022 – 2030 8.2.5.5.4. Middle East and Africa 8.2.5.5.4.1. Market Estimation, 2015 - 2021 8.2.5.5.4.2. Market Forecast, 2022 – 2030 8.2.5.5.5. Latin America 8.2.5.5.5.1. Market Estimation, 2015 - 2021 8.2.5.5.5.2. Market Forecast, 2022 – 2030 8.3. Key Segment for Channeling Investments 8.3.1. By Indication 9. Global Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 9.1. Overview 9.2. Global Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 9.2.1. Blood Tests 9.2.1.1. Definition 9.2.1.2. Market Estimation and Penetration, 2015 - 2021 9.2.1.3. Market Forecast, 2022 – 2030 9.2.1.4. Compound Annual Growth Rate (CAGR) 9.2.1.5. Regional Bifurcation 9.2.1.5.1. North America 9.2.1.5.1.1. Market Estimation, 2015 - 2021 9.2.1.5.1.2. Market Forecast, 2022 – 2030 9.2.1.5.2. Europe 9.2.1.5.2.1. Market Estimation, 2015 - 2021 9.2.1.5.2.2. Market Forecast, 2022 – 2030 9.2.1.5.3. Asia Pacific 9.2.1.5.3.1. Market Estimation, 2015 - 2021 9.2.1.5.3.2. Market Forecast, 2022 – 2030 9.2.1.5.4. Middle East and Africa 9.2.1.5.4.1. Market Estimation, 2015 - 2021 9.2.1.5.4.2. Market Forecast, 2022 – 2030 9.2.1.5.5. Latin America 9.2.1.5.5.1. Market Estimation, 2015 - 2021 9.2.1.5.5.2. Market Forecast, 2022 – 2030 9.2.2. Computerized Tomography (CT) scan 9.2.2.1. Definition 9.2.2.2. Market Estimation and Penetration, 2015 - 2021 9.2.2.3. Market Forecast, 2022 – 2030 9.2.2.4. Compound Annual Growth Rate (CAGR) 9.2.2.5. Regional Bifurcation 9.2.2.5.1. North America 9.2.2.5.1.1. Market Estimation, 2015 - 2021 9.2.2.5.1.2. Market Forecast, 2022 – 2030 9.2.2.5.2. Europe 9.2.2.5.2.1. Market Estimation, 2015 - 2021 9.2.2.5.2.2. Market Forecast, 2022 – 2030 9.2.2.5.3. Asia Pacific 9.2.2.5.3.1. Market Estimation, 2015 - 2021 9.2.2.5.3.2. Market Forecast, 2022 – 2030 9.2.2.5.4. Middle East and Africa 9.2.2.5.4.1. Market Estimation, 2015 - 2021 9.2.2.5.4.2. Market Forecast, 2022 – 2030 9.2.2.5.5. Latin America 9.2.2.5.5.1. Market Estimation, 2015 - 2021 9.2.2.5.5.2. Market Forecast, 2022 – 2030 9.2.3. Fecal fat tests 9.2.3.1. Definition 9.2.3.2. Market Estimation and Penetration, 2015 - 2021 9.2.3.3. Market Forecast, 2022 – 2030 9.2.3.4. Compound Annual Growth Rate (CAGR) 9.2.3.5. Regional Bifurcation 9.2.3.5.1. North America 9.2.3.5.1.1. Market Estimation, 2015 - 2021 9.2.3.5.1.2. Market Forecast, 2022 – 2030 9.2.3.5.2. Europe 9.2.3.5.2.1. Market Estimation, 2015 - 2021 9.2.3.5.2.2. Market Forecast, 2022 – 2030 9.2.3.5.3. Asia Pacific 9.2.3.5.3.1. Market Estimation, 2015 - 2021 9.2.3.5.3.2. Market Forecast, 2022 – 2030 9.2.3.5.4. Middle East and Africa 9.2.3.5.4.1. Market Estimation, 2015 - 2021 9.2.3.5.4.2. Market Forecast, 2022 – 2030 9.2.3.5.5. Latin America 9.2.3.5.5.1. Market Estimation, 2015 - 2021 9.2.3.5.5.2. Market Forecast, 2022 – 2030 9.2.4. Upper Gastrointestinal (GI) Series 9.2.4.1. Definition 9.2.4.2. Market Estimation and Penetration, 2015 - 2021 9.2.4.3. Market Forecast, 2022 – 2030 9.2.4.4. Compound Annual Growth Rate (CAGR) 9.2.4.5. Regional Bifurcation 9.2.4.5.1. North America 9.2.4.5.1.1. Market Estimation, 2015 - 2021 9.2.4.5.1.2. Market Forecast, 2022 – 2030 9.2.4.5.2. Europe 9.2.4.5.2.1. Market Estimation, 2015 - 2021 9.2.4.5.2.2. Market Forecast, 2022 – 2030 9.2.4.5.3. Asia Pacific 9.2.4.5.3.1. Market Estimation, 2015 - 2021 9.2.4.5.3.2. Market Forecast, 2022 – 2030 9.2.4.5.4. Middle East and Africa 9.2.4.5.4.1. Market Estimation, 2015 - 2021 9.2.4.5.4.2. Market Forecast, 2022 – 2030 9.2.4.5.5. Latin America 9.2.4.5.5.1. Market Estimation, 2015 - 2021 9.2.4.5.5.2. Market Forecast, 2022 – 2030 9.2.5. X-ray 9.2.5.1. Definition 9.2.5.2. Market Estimation and Penetration, 2015 - 2021 9.2.5.3. Market Forecast, 2022 – 2030 9.2.5.4. Compound Annual Growth Rate (CAGR) 9.2.5.5. Regional Bifurcation 9.2.5.5.1. North America 9.2.5.5.1.1. Market Estimation, 2015 - 2021 9.2.5.5.1.2. Market Forecast, 2022 – 2030 9.2.5.5.2. Europe 9.2.5.5.2.1. Market Estimation, 2015 - 2021 9.2.5.5.2.2. Market Forecast, 2022 – 2030 9.2.5.5.3. Asia Pacific 9.2.5.5.3.1. Market Estimation, 2015 - 2021 9.2.5.5.3.2. Market Forecast, 2022 – 2030 9.2.5.5.4. Middle East and Africa 9.2.5.5.4.1. Market Estimation, 2015 - 2021 9.2.5.5.4.2. Market Forecast, 2022 – 2030 9.2.5.5.5. Latin America 9.2.5.5.5.1. Market Estimation, 2015 - 2021 9.2.5.5.5.2. Market Forecast, 2022 – 2030 9.2.6. Liver Biopsy 9.2.6.1. Definition 9.2.6.2. Market Estimation and Penetration, 2015 - 2021 9.2.6.3. Market Forecast, 2022 – 2030 9.2.6.4. Compound Annual Growth Rate (CAGR) 9.2.6.5. Regional Bifurcation 9.2.6.5.1. North America 9.2.6.5.1.1. Market Estimation, 2015 - 2021 9.2.6.5.1.2. Market Forecast, 2022 – 2030 9.2.6.5.2. Europe 9.2.6.5.2.1. Market Estimation, 2015 - 2021 9.2.6.5.2.2. Market Forecast, 2022 – 2030 9.2.6.5.3. Asia Pacific 9.2.6.5.3.1. Market Estimation, 2015 - 2021 9.2.6.5.3.2. Market Forecast, 2022 – 2030 9.2.6.5.4. Middle East and Africa 9.2.6.5.4.1. Market Estimation, 2015 - 2021 9.2.6.5.4.2. Market Forecast, 2022 – 2030 9.2.6.5.5. Latin America 9.2.6.5.5.1. Market Estimation, 2015 - 2021 9.2.6.5.5.2. Market Forecast, 2022 – 2030 9.2.7. Others 9.2.7.1. Definition 9.2.7.2. Market Estimation and Penetration, 2015 - 2021 9.2.7.3. Market Forecast, 2022 – 2030 9.2.7.4. Compound Annual Growth Rate (CAGR) 9.2.7.5. Regional Bifurcation 9.2.7.5.1. North America 9.2.7.5.1.1. Market Estimation, 2015 - 2021 9.2.7.5.1.2. Market Forecast, 2022 – 2030 9.2.7.5.2. Europe 9.2.7.5.2.1. Market Estimation, 2015 - 2021 9.2.7.5.2.2. Market Forecast, 2022 – 2030 9.2.7.5.3. Asia Pacific 9.2.7.5.3.1. Market Estimation, 2015 - 2021 9.2.7.5.3.2. Market Forecast, 2022 – 2030 9.2.7.5.4. Middle East and Africa 9.2.7.5.4.1. Market Estimation, 2015 - 2021 9.2.7.5.4.2. Market Forecast, 2022 – 2030 9.2.7.5.5. Latin America 9.2.7.5.5.1. Market Estimation, 2015 - 2021 9.2.7.5.5.2. Market Forecast, 2022 – 2030 9.3. Key Segment for Channeling Investments 9.3.1. By Diagnosis 10. Global Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 10.1. Overview 10.2. Global Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 10.2.1. Nutritional support (Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Oral rehydration, Parenteral nutrition., Vitamin and mineral supplements, Special Diet, Others) 10.2.1.1. Oral rehydration 10.2.1.2. Parenteral nutrition. 10.2.1.3. Vitamin and mineral supplements 10.2.1.4. Special Diet 10.2.1.5. Others 10.2.2. Medications (Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on GLP-2 , Glutamine , Growth Hormones, Others) 10.2.2.1. GLP-2 10.2.2.2. Glutamine 10.2.2.3. Growth Hormones 10.2.2.4. Others 10.2.3. Intestinal transplant surgery 10.2.3.1. Definition 10.2.3.2. Market Estimation and Penetration, 2015 - 2021 10.2.3.3. Market Forecast, 2022 – 2030 10.2.3.4. Compound Annual Growth Rate (CAGR) 10.2.3.5. Regional Bifurcation 10.2.3.5.1. North America 10.2.3.5.1.1. Market Estimation, 2015 - 2021 10.2.3.5.1.2. Market Forecast, 2022 – 2030 10.2.3.5.2. Europe 10.2.3.5.2.1. Market Estimation, 2015 - 2021 10.2.3.5.2.2. Market Forecast, 2022 – 2030 10.2.3.5.3. Asia Pacific 10.2.3.5.3.1. Market Estimation, 2015 - 2021 10.2.3.5.3.2. Market Forecast, 2022 – 2030 10.2.3.5.4. Middle East and Africa 10.2.3.5.4.1. Market Estimation, 2015 - 2021 10.2.3.5.4.2. Market Forecast, 2022 – 2030 10.2.3.5.5. Latin America 10.2.3.5.5.1. Market Estimation, 2015 - 2021 10.2.3.5.5.2. Market Forecast, 2022 – 2030 10.2.4. Others 10.2.4.1. Definition 10.2.4.2. Market Estimation and Penetration, 2015 - 2021 10.2.4.3. Market Forecast, 2022 – 2030 10.2.4.4. Compound Annual Growth Rate (CAGR) 10.2.4.5. Regional Bifurcation 10.2.4.5.1. North America 10.2.4.5.1.1. Market Estimation, 2015 - 2021 10.2.4.5.1.2. Market Forecast, 2022 – 2030 10.2.4.5.2. Europe 10.2.4.5.2.1. Market Estimation, 2015 - 2021 10.2.4.5.2.2. Market Forecast, 2022 – 2030 10.2.4.5.3. Asia Pacific 10.2.4.5.3.1. Market Estimation, 2015 - 2021 10.2.4.5.3.2. Market Forecast, 2022 – 2030 10.2.4.5.4. Middle East and Africa 10.2.4.5.4.1. Market Estimation, 2015 - 2021 10.2.4.5.4.2. Market Forecast, 2022 – 2030 10.2.4.5.5. Latin America 10.2.4.5.5.1. Market Estimation, 2015 - 2021 10.2.4.5.5.2. Market Forecast, 2022 – 2030 10.3. Key Segment for Channeling Investments 10.3.1. By Treatment 11. Global Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 11.1. Overview 11.2. Global Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 11.2.1. Infants / Children 11.2.1.1. Definition 11.2.1.2. Market Estimation and Penetration, 2015 - 2021 11.2.1.3. Market Forecast, 2022 – 2030 11.2.1.4. Compound Annual Growth Rate (CAGR) 11.2.1.5. Regional Bifurcation 11.2.1.5.1. North America 11.2.1.5.1.1. Market Estimation, 2015 - 2021 11.2.1.5.1.2. Market Forecast, 2022 – 2030 11.2.1.5.2. Europe 11.2.1.5.2.1. Market Estimation, 2015 - 2021 11.2.1.5.2.2. Market Forecast, 2022 – 2030 11.2.1.5.3. Asia Pacific 11.2.1.5.3.1. Market Estimation, 2015 - 2021 11.2.1.5.3.2. Market Forecast, 2022 – 2030 11.2.1.5.4. Middle East and Africa 11.2.1.5.4.1. Market Estimation, 2015 - 2021 11.2.1.5.4.2. Market Forecast, 2022 – 2030 11.2.1.5.5. Latin America 11.2.1.5.5.1. Market Estimation, 2015 - 2021 11.2.1.5.5.2. Market Forecast, 2022 – 2030 11.2.2. Adults 11.2.2.1. Definition 11.2.2.2. Market Estimation and Penetration, 2015 - 2021 11.2.2.3. Market Forecast, 2022 – 2030 11.2.2.4. Compound Annual Growth Rate (CAGR) 11.2.2.5. Regional Bifurcation 11.2.2.5.1. North America 11.2.2.5.1.1. Market Estimation, 2015 - 2021 11.2.2.5.1.2. Market Forecast, 2022 – 2030 11.2.2.5.2. Europe 11.2.2.5.2.1. Market Estimation, 2015 - 2021 11.2.2.5.2.2. Market Forecast, 2022 – 2030 11.2.2.5.3. Asia Pacific 11.2.2.5.3.1. Market Estimation, 2015 - 2021 11.2.2.5.3.2. Market Forecast, 2022 – 2030 11.2.2.5.4. Middle East and Africa 11.2.2.5.4.1. Market Estimation, 2015 - 2021 11.2.2.5.4.2. Market Forecast, 2022 – 2030 11.2.2.5.5. Latin America 11.2.2.5.5.1. Market Estimation, 2015 - 2021 11.2.2.5.5.2. Market Forecast, 2022 – 2030 11.3. Key Segment for Channeling Investments 11.3.1. By Application 12. Global Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 12.1. Overview 12.2. Global Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 12.2.1. Gastrointestinal Specialty Clinics 12.2.1.1. Definition 12.2.1.2. Market Estimation and Penetration, 2015 - 2021 12.2.1.3. Market Forecast, 2022 – 2030 12.2.1.4. Compound Annual Growth Rate (CAGR) 12.2.1.5. Regional Bifurcation 12.2.1.5.1. North America 12.2.1.5.1.1. Market Estimation, 2015 - 2021 12.2.1.5.1.2. Market Forecast, 2022 – 2030 12.2.1.5.2. Europe 12.2.1.5.2.1. Market Estimation, 2015 - 2021 12.2.1.5.2.2. Market Forecast, 2022 – 2030 12.2.1.5.3. Asia Pacific 12.2.1.5.3.1. Market Estimation, 2015 - 2021 12.2.1.5.3.2. Market Forecast, 2022 – 2030 12.2.1.5.4. Middle East and Africa 12.2.1.5.4.1. Market Estimation, 2015 - 2021 12.2.1.5.4.2. Market Forecast, 2022 – 2030 12.2.1.5.5. Latin America 12.2.1.5.5.1. Market Estimation, 2015 - 2021 12.2.1.5.5.2. Market Forecast, 2022 – 2030 12.2.2. Hospitals 12.2.2.1. Definition 12.2.2.2. Market Estimation and Penetration, 2015 - 2021 12.2.2.3. Market Forecast, 2022 – 2030 12.2.2.4. Compound Annual Growth Rate (CAGR) 12.2.2.5. Regional Bifurcation 12.2.2.5.1. North America 12.2.2.5.1.1. Market Estimation, 2015 - 2021 12.2.2.5.1.2. Market Forecast, 2022 – 2030 12.2.2.5.2. Europe 12.2.2.5.2.1. Market Estimation, 2015 - 2021 12.2.2.5.2.2. Market Forecast, 2022 – 2030 12.2.2.5.3. Asia Pacific 12.2.2.5.3.1. Market Estimation, 2015 - 2021 12.2.2.5.3.2. Market Forecast, 2022 – 2030 12.2.2.5.4. Middle East and Africa 12.2.2.5.4.1. Market Estimation, 2015 - 2021 12.2.2.5.4.2. Market Forecast, 2022 – 2030 12.2.2.5.5. Latin America 12.2.2.5.5.1. Market Estimation, 2015 - 2021 12.2.2.5.5.2. Market Forecast, 2022 – 2030 12.2.3. Others 12.2.3.1. Definition 12.2.3.2. Market Estimation and Penetration, 2015 - 2021 12.2.3.3. Market Forecast, 2022 – 2030 12.2.3.4. Compound Annual Growth Rate (CAGR) 12.2.3.5. Regional Bifurcation 12.2.3.5.1. North America 12.2.3.5.1.1. Market Estimation, 2015 - 2021 12.2.3.5.1.2. Market Forecast, 2022 – 2030 12.2.3.5.2. Europe 12.2.3.5.2.1. Market Estimation, 2015 - 2021 12.2.3.5.2.2. Market Forecast, 2022 – 2030 12.2.3.5.3. Asia Pacific 12.2.3.5.3.1. Market Estimation, 2015 - 2021 12.2.3.5.3.2. Market Forecast, 2022 – 2030 12.2.3.5.4. Middle East and Africa 12.2.3.5.4.1. Market Estimation, 2015 - 2021 12.2.3.5.4.2. Market Forecast, 2022 – 2030 12.2.3.5.5. Latin America 12.2.3.5.5.1. Market Estimation, 2015 - 2021 12.2.3.5.5.2. Market Forecast, 2022 – 2030 12.3. Key Segment for Channeling Investments 12.3.1. By End User 13. North America Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 13.1. Overview 13.1.1. North America Short Bowel Syndrome Market Revenue (US$ Mn) 13.2. North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 13.2.1. Diarrhea 13.2.2. Fatigue 13.2.3. Weight loss 13.2.4. Malnutrition 13.2.5. Others 13.3. North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 13.3.1. Blood Tests 13.3.2. Computerized Tomography (CT) scan 13.3.3. Fecal fat tests 13.3.4. Upper Gastrointestinal (GI) Series 13.3.5. X-ray 13.3.6. Liver Biopsy 13.3.7. Others 13.4. North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 13.4.1. Nutritional support 13.4.1.1. Oral rehydration 13.4.1.2. Parenteral nutrition. 13.4.1.3. Vitamin and mineral supplements 13.4.1.4. Special Diet 13.4.1.5. Others 13.4.2. Medications 13.4.2.1. GLP-2 13.4.2.2. Glutamine 13.4.2.3. Growth Hormones 13.4.2.4. Others 13.4.3. Intestinal transplant surgery 13.4.4. Others 13.5. North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 13.5.1. Infants / Children 13.5.2. Adults 13.6. North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 13.6.1. Gastrointestinal Specialty Clinics 13.6.2. Hospitals 13.6.3. Others 13.7. North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 13.7.1. U.S 13.7.1.1. U.S Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 13.7.1.1.1. Diarrhea 13.7.1.1.2. Fatigue 13.7.1.1.3. Weight loss 13.7.1.1.4. Malnutrition 13.7.1.1.5. Others 13.7.1.2. U.S Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 13.7.1.2.1. Blood Tests 13.7.1.2.2. Computerized Tomography (CT) scan 13.7.1.2.3. Fecal fat tests 13.7.1.2.4. Upper Gastrointestinal (GI) Series 13.7.1.2.5. X-ray 13.7.1.2.6. Liver Biopsy 13.7.1.2.7. Others 13.7.1.3. U.S Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 13.7.1.3.1. Nutritional support 13.7.1.3.1.1. Oral rehydration 13.7.1.3.1.2. Parenteral nutrition. 13.7.1.3.1.3. Vitamin and mineral supplements 13.7.1.3.1.4. Special Diet 13.7.1.3.1.5. Others 13.7.1.3.2. Medications 13.7.1.3.2.1. GLP-2 13.7.1.3.2.2. Glutamine 13.7.1.3.2.3. Growth Hormones 13.7.1.3.2.4. Others 13.7.1.3.3. Intestinal transplant surgery 13.7.1.3.4. Others 13.7.1.4. U.S Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 13.7.1.4.1. Infants / Children 13.7.1.4.2. Adults 13.7.1.5. U.S Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 13.7.1.5.1. Gastrointestinal Specialty Clinics 13.7.1.5.2. Hospitals 13.7.1.5.3. Others 13.7.2. Canada 13.7.2.1. Canada Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 13.7.2.1.1. Diarrhea 13.7.2.1.2. Fatigue 13.7.2.1.3. Weight loss 13.7.2.1.4. Malnutrition 13.7.2.1.5. Others 13.7.2.2. Canada Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 13.7.2.2.1. Blood Tests 13.7.2.2.2. Computerized Tomography (CT) scan 13.7.2.2.3. Fecal fat tests 13.7.2.2.4. Upper Gastrointestinal (GI) Series 13.7.2.2.5. X-ray 13.7.2.2.6. Liver Biopsy 13.7.2.2.7. Others 13.7.2.3. Canada Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 13.7.2.3.1. Nutritional support 13.7.2.3.1.1. Oral rehydration 13.7.2.3.1.2. Parenteral nutrition. 13.7.2.3.1.3. Vitamin and mineral supplements 13.7.2.3.1.4. Special Diet 13.7.2.3.1.5. Others 13.7.2.3.2. Medications 13.7.2.3.2.1. GLP-2 13.7.2.3.2.2. Glutamine 13.7.2.3.2.3. Growth Hormones 13.7.2.3.2.4. Others 13.7.2.3.3. Intestinal transplant surgery 13.7.2.3.4. Others 13.7.2.4. Canada Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 13.7.2.4.1. Infants / Children 13.7.2.4.2. Adults 13.7.2.5. Canada Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 13.7.2.5.1. Gastrointestinal Specialty Clinics 13.7.2.5.2. Hospitals 13.7.2.5.3. Others 13.7.3. Mexico 13.7.3.1. Mexico Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 13.7.3.1.1. Diarrhea 13.7.3.1.2. Fatigue 13.7.3.1.3. Weight loss 13.7.3.1.4. Malnutrition 13.7.3.1.5. Others 13.7.3.2. Mexico Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 13.7.3.2.1. Blood Tests 13.7.3.2.2. Computerized Tomography (CT) scan 13.7.3.2.3. Fecal fat tests 13.7.3.2.4. Upper Gastrointestinal (GI) Series 13.7.3.2.5. X-ray 13.7.3.2.6. Liver Biopsy 13.7.3.2.7. Others 13.7.3.3. Mexico Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 13.7.3.3.1. Nutritional support 13.7.3.3.1.1. Oral rehydration 13.7.3.3.1.2. Parenteral nutrition. 13.7.3.3.1.3. Vitamin and mineral supplements 13.7.3.3.1.4. Special Diet 13.7.3.3.1.5. Others 13.7.3.3.2. Medications 13.7.3.3.2.1. GLP-2 13.7.3.3.2.2. Glutamine 13.7.3.3.2.3. Growth Hormones 13.7.3.3.2.4. Others 13.7.3.3.3. Intestinal transplant surgery 13.7.3.3.4. Others 13.7.3.4. Mexico Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 13.7.3.4.1. Infants / Children 13.7.3.4.2. Adults 13.7.3.5. Mexico Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 13.7.3.5.1. Gastrointestinal Specialty Clinics 13.7.3.5.2. Hospitals 13.7.3.5.3. Others 13.7.4. Rest of North America 13.7.4.1. Rest of North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 13.7.4.1.1. Diarrhea 13.7.4.1.2. Fatigue 13.7.4.1.3. Weight loss 13.7.4.1.4. Malnutrition 13.7.4.1.5. Others 13.7.4.2. Rest of North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 13.7.4.2.1. Blood Tests 13.7.4.2.2. Computerized Tomography (CT) scan 13.7.4.2.3. Fecal fat tests 13.7.4.2.4. Upper Gastrointestinal (GI) Series 13.7.4.2.5. X-ray 13.7.4.2.6. Liver Biopsy 13.7.4.2.7. Others 13.7.4.3. Rest of North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 13.7.4.3.1. Nutritional support 13.7.4.3.1.1. Oral rehydration 13.7.4.3.1.2. Parenteral nutrition. 13.7.4.3.1.3. Vitamin and mineral supplements 13.7.4.3.1.4. Special Diet 13.7.4.3.1.5. Others 13.7.4.3.2. Medications 13.7.4.3.2.1. GLP-2 13.7.4.3.2.2. Glutamine 13.7.4.3.2.3. Growth Hormones 13.7.4.3.2.4. Others 13.7.4.3.3. Intestinal transplant surgery 13.7.4.3.4. Others 13.7.4.4. Rest of North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 13.7.4.4.1. Infants / Children 13.7.4.4.2. Adults 13.7.4.5. Rest of North America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 13.7.4.5.1. Gastrointestinal Specialty Clinics 13.7.4.5.2. Hospitals 13.7.4.5.3. Others 13.8. Key Segment for Channeling Investments 13.8.1. By Country 13.8.2. By Indication 13.8.3. By Diagnosis 13.8.4. By Treatment 13.8.5. By Application 13.8.6. By End User 14. Europe Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 14.1. Overview 14.1.1. Europe Short Bowel Syndrome Market Revenue (US$ Mn) 14.2. Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.2.1. Diarrhea 14.2.2. Fatigue 14.2.3. Weight loss 14.2.4. Malnutrition 14.2.5. Others 14.3. Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.3.1. Blood Tests 14.3.2. Computerized Tomography (CT) scan 14.3.3. Fecal fat tests 14.3.4. Upper Gastrointestinal (GI) Series 14.3.5. X-ray 14.3.6. Liver Biopsy 14.3.7. Others 14.4. Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.4.1. Nutritional support 14.4.1.1. Oral rehydration 14.4.1.2. Parenteral nutrition. 14.4.1.3. Vitamin and mineral supplements 14.4.1.4. Special Diet 14.4.1.5. Others 14.4.2. Medications 14.4.2.1. GLP-2 14.4.2.2. Glutamine 14.4.2.3. Growth Hormones 14.4.2.4. Others 14.4.3. Intestinal transplant surgery 14.4.4. Others 14.5. Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.5.1. Infants / Children 14.5.2. Adults 14.6. Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.6.1. Gastrointestinal Specialty Clinics 14.6.2. Hospitals 14.6.3. Others 14.7. Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 14.7.1. France 14.7.1.1. France Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.1.1.1. Diarrhea 14.7.1.1.2. Fatigue 14.7.1.1.3. Weight loss 14.7.1.1.4. Malnutrition 14.7.1.1.5. Others 14.7.1.2. France Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.1.2.1. Blood Tests 14.7.1.2.2. Computerized Tomography (CT) scan 14.7.1.2.3. Fecal fat tests 14.7.1.2.4. Upper Gastrointestinal (GI) Series 14.7.1.2.5. X-ray 14.7.1.2.6. Liver Biopsy 14.7.1.2.7. Others 14.7.1.3. France Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.1.3.1. Nutritional support 14.7.1.3.1.1. Oral rehydration 14.7.1.3.1.2. Parenteral nutrition. 14.7.1.3.1.3. Vitamin and mineral supplements 14.7.1.3.1.4. Special Diet 14.7.1.3.1.5. Others 14.7.1.3.2. Medications 14.7.1.3.2.1. GLP-2 14.7.1.3.2.2. Glutamine 14.7.1.3.2.3. Growth Hormones 14.7.1.3.2.4. Others 14.7.1.3.3. Intestinal transplant surgery 14.7.1.3.4. Others 14.7.1.4. France Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.1.4.1. Infants / Children 14.7.1.4.2. Adults 14.7.1.5. France Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.1.5.1. Gastrointestinal Specialty Clinics 14.7.1.5.2. Hospitals 14.7.1.5.3. Others 14.7.2. The UK 14.7.2.1. The UK Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.2.1.1. Diarrhea 14.7.2.1.2. Fatigue 14.7.2.1.3. Weight loss 14.7.2.1.4. Malnutrition 14.7.2.1.5. Others 14.7.2.2. The UK Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.2.2.1. Blood Tests 14.7.2.2.2. Computerized Tomography (CT) scan 14.7.2.2.3. Fecal fat tests 14.7.2.2.4. Upper Gastrointestinal (GI) Series 14.7.2.2.5. X-ray 14.7.2.2.6. Liver Biopsy 14.7.2.2.7. Others 14.7.2.3. The UK Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.2.3.1. Nutritional support 14.7.2.3.1.1. Oral rehydration 14.7.2.3.1.2. Parenteral nutrition. 14.7.2.3.1.3. Vitamin and mineral supplements 14.7.2.3.1.4. Special Diet 14.7.2.3.1.5. Others 14.7.2.3.2. Medications 14.7.2.3.2.1. GLP-2 14.7.2.3.2.2. Glutamine 14.7.2.3.2.3. Growth Hormones 14.7.2.3.2.4. Others 14.7.2.3.3. Intestinal transplant surgery 14.7.2.3.4. Others 14.7.2.4. The UK Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.2.4.1. Infants / Children 14.7.2.4.2. Adults 14.7.2.5. The UK Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.2.5.1. Gastrointestinal Specialty Clinics 14.7.2.5.2. Hospitals 14.7.2.5.3. Others 14.7.3. Spain 14.7.3.1. Spain Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.3.1.1. Diarrhea 14.7.3.1.2. Fatigue 14.7.3.1.3. Weight loss 14.7.3.1.4. Malnutrition 14.7.3.1.5. Others 14.7.3.2. Spain Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.3.2.1. Blood Tests 14.7.3.2.2. Computerized Tomography (CT) scan 14.7.3.2.3. Fecal fat tests 14.7.3.2.4. Upper Gastrointestinal (GI) Series 14.7.3.2.5. X-ray 14.7.3.2.6. Liver Biopsy 14.7.3.2.7. Others 14.7.3.3. Spain Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.3.3.1. Nutritional support 14.7.3.3.1.1. Oral rehydration 14.7.3.3.1.2. Parenteral nutrition. 14.7.3.3.1.3. Vitamin and mineral supplements 14.7.3.3.1.4. Special Diet 14.7.3.3.1.5. Others 14.7.3.3.2. Medications 14.7.3.3.2.1. GLP-2 14.7.3.3.2.2. Glutamine 14.7.3.3.2.3. Growth Hormones 14.7.3.3.2.4. Others 14.7.3.3.3. Intestinal transplant surgery 14.7.3.3.4. Others 14.7.3.4. Spain Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.3.4.1. Infants / Children 14.7.3.4.2. Adults 14.7.3.5. Spain Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.3.5.1. Gastrointestinal Specialty Clinics 14.7.3.5.2. Hospitals 14.7.3.5.3. Others 14.7.4. Germany 14.7.4.1. Germany Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.4.1.1. Diarrhea 14.7.4.1.2. Fatigue 14.7.4.1.3. Weight loss 14.7.4.1.4. Malnutrition 14.7.4.1.5. Others 14.7.4.2. Germany Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.4.2.1. Blood Tests 14.7.4.2.2. Computerized Tomography (CT) scan 14.7.4.2.3. Fecal fat tests 14.7.4.2.4. Upper Gastrointestinal (GI) Series 14.7.4.2.5. X-ray 14.7.4.2.6. Liver Biopsy 14.7.4.2.7. Others 14.7.4.3. Germany Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.4.3.1. Nutritional support 14.7.4.3.1.1. Oral rehydration 14.7.4.3.1.2. Parenteral nutrition. 14.7.4.3.1.3. Vitamin and mineral supplements 14.7.4.3.1.4. Special Diet 14.7.4.3.1.5. Others 14.7.4.3.2. Medications 14.7.4.3.2.1. GLP-2 14.7.4.3.2.2. Glutamine 14.7.4.3.2.3. Growth Hormones 14.7.4.3.2.4. Others 14.7.4.3.3. Intestinal transplant surgery 14.7.4.3.4. Others 14.7.4.4. Germany Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.4.4.1. Infants / Children 14.7.4.4.2. Adults 14.7.4.5. Germany Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.4.5.1. Gastrointestinal Specialty Clinics 14.7.4.5.2. Hospitals 14.7.4.5.3. Others 14.7.5. Italy 14.7.5.1. Italy Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.5.1.1. Diarrhea 14.7.5.1.2. Fatigue 14.7.5.1.3. Weight loss 14.7.5.1.4. Malnutrition 14.7.5.1.5. Others 14.7.5.2. Italy Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.5.2.1. Blood Tests 14.7.5.2.2. Computerized Tomography (CT) scan 14.7.5.2.3. Fecal fat tests 14.7.5.2.4. Upper Gastrointestinal (GI) Series 14.7.5.2.5. X-ray 14.7.5.2.6. Liver Biopsy 14.7.5.2.7. Others 14.7.5.3. Italy Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.5.3.1. Nutritional support 14.7.5.3.1.1. Oral rehydration 14.7.5.3.1.2. Parenteral nutrition. 14.7.5.3.1.3. Vitamin and mineral supplements 14.7.5.3.1.4. Special Diet 14.7.5.3.1.5. Others 14.7.5.3.2. Medications 14.7.5.3.2.1. GLP-2 14.7.5.3.2.2. Glutamine 14.7.5.3.2.3. Growth Hormones 14.7.5.3.2.4. Others 14.7.5.3.3. Intestinal transplant surgery 14.7.5.3.4. Others 14.7.5.4. Italy Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.5.4.1. Infants / Children 14.7.5.4.2. Adults 14.7.5.5. Italy Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.5.5.1. Gastrointestinal Specialty Clinics 14.7.5.5.2. Hospitals 14.7.5.5.3. Others 14.7.6. Nordic Countries 14.7.6.1. Nordic Countries Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.6.1.1. Diarrhea 14.7.6.1.2. Fatigue 14.7.6.1.3. Weight loss 14.7.6.1.4. Malnutrition 14.7.6.1.5. Others 14.7.6.2. Nordic Countries Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.6.2.1. Blood Tests 14.7.6.2.2. Computerized Tomography (CT) scan 14.7.6.2.3. Fecal fat tests 14.7.6.2.4. Upper Gastrointestinal (GI) Series 14.7.6.2.5. X-ray 14.7.6.2.6. Liver Biopsy 14.7.6.2.7. Others 14.7.6.3. Nordic Countries Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.6.3.1. Nutritional support 14.7.6.3.1.1. Oral rehydration 14.7.6.3.1.2. Parenteral nutrition. 14.7.6.3.1.3. Vitamin and mineral supplements 14.7.6.3.1.4. Special Diet 14.7.6.3.1.5. Others 14.7.6.3.2. Medications 14.7.6.3.2.1. GLP-2 14.7.6.3.2.2. Glutamine 14.7.6.3.2.3. Growth Hormones 14.7.6.3.2.4. Others 14.7.6.3.3. Intestinal transplant surgery 14.7.6.3.4. Others 14.7.6.4. Nordic Countries Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.6.4.1. Infants / Children 14.7.6.4.2. Adults 14.7.6.5. Nordic Countries Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.6.5.1. Gastrointestinal Specialty Clinics 14.7.6.5.2. Hospitals 14.7.6.5.3. Others 14.7.6.6. Nordic Countries Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 14.7.6.6.1. Denmark 14.7.6.6.2. Finland 14.7.6.6.3. Iceland 14.7.6.6.4. Sweden 14.7.6.6.5. Norway 14.7.7. Benelux Union 14.7.7.1. Benelux Union Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.7.1.1. Diarrhea 14.7.7.1.2. Fatigue 14.7.7.1.3. Weight loss 14.7.7.1.4. Malnutrition 14.7.7.1.5. Others 14.7.7.2. Benelux Union Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.7.2.1. Blood Tests 14.7.7.2.2. Computerized Tomography (CT) scan 14.7.7.2.3. Fecal fat tests 14.7.7.2.4. Upper Gastrointestinal (GI) Series 14.7.7.2.5. X-ray 14.7.7.2.6. Liver Biopsy 14.7.7.2.7. Others 14.7.7.3. Benelux Union Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.7.3.1. Nutritional support 14.7.7.3.1.1. Oral rehydration 14.7.7.3.1.2. Parenteral nutrition. 14.7.7.3.1.3. Vitamin and mineral supplements 14.7.7.3.1.4. Special Diet 14.7.7.3.1.5. Others 14.7.7.3.2. Medications 14.7.7.3.2.1. GLP-2 14.7.7.3.2.2. Glutamine 14.7.7.3.2.3. Growth Hormones 14.7.7.3.2.4. Others 14.7.7.3.3. Intestinal transplant surgery 14.7.7.3.4. Others 14.7.7.4. Benelux Union Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.7.4.1. Infants / Children 14.7.7.4.2. Adults 14.7.7.5. Benelux Union Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.7.5.1. Gastrointestinal Specialty Clinics 14.7.7.5.2. Hospitals 14.7.7.5.3. Others 14.7.7.6. Benelux Union Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 14.7.7.6.1. Belgium 14.7.7.6.2. The Netherlands 14.7.7.6.3. Luxembourg 14.7.8. Rest of Europe 14.7.8.1. Rest of Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 14.7.8.1.1. Diarrhea 14.7.8.1.2. Fatigue 14.7.8.1.3. Weight loss 14.7.8.1.4. Malnutrition 14.7.8.1.5. Others 14.7.8.2. Rest of Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 14.7.8.2.1. Blood Tests 14.7.8.2.2. Computerized Tomography (CT) scan 14.7.8.2.3. Fecal fat tests 14.7.8.2.4. Upper Gastrointestinal (GI) Series 14.7.8.2.5. X-ray 14.7.8.2.6. Liver Biopsy 14.7.8.2.7. Others 14.7.8.3. Rest of Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 14.7.8.3.1. Nutritional support 14.7.8.3.1.1. Oral rehydration 14.7.8.3.1.2. Parenteral nutrition. 14.7.8.3.1.3. Vitamin and mineral supplements 14.7.8.3.1.4. Special Diet 14.7.8.3.1.5. Others 14.7.8.3.2. Medications 14.7.8.3.2.1. GLP-2 14.7.8.3.2.2. Glutamine 14.7.8.3.2.3. Growth Hormones 14.7.8.3.2.4. Others 14.7.8.3.3. Intestinal transplant surgery 14.7.8.3.4. Others 14.7.8.4. Rest of Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 14.7.8.4.1. Infants / Children 14.7.8.4.2. Adults 14.7.8.5. Rest of Europe Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 14.7.8.5.1. Gastrointestinal Specialty Clinics 14.7.8.5.2. Hospitals 14.7.8.5.3. Others 14.8. Key Segment for Channeling Investments 14.8.1. By Country 14.8.2. By Indication 14.8.3. By Diagnosis 14.8.4. By Treatment 14.8.5. By Application 14.8.6. By End User 15. Asia Pacific Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 15.1. Overview 15.1.1. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) 15.2. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.2.1. Diarrhea 15.2.2. Fatigue 15.2.3. Weight loss 15.2.4. Malnutrition 15.2.5. Others 15.3. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.3.1. Blood Tests 15.3.2. Computerized Tomography (CT) scan 15.3.3. Fecal fat tests 15.3.4. Upper Gastrointestinal (GI) Series 15.3.5. X-ray 15.3.6. Liver Biopsy 15.3.7. Others 15.4. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.4.1. Nutritional support 15.4.1.1. Oral rehydration 15.4.1.2. Parenteral nutrition. 15.4.1.3. Vitamin and mineral supplements 15.4.1.4. Special Diet 15.4.1.5. Others 15.4.2. Medications 15.4.2.1. GLP-2 15.4.2.2. Glutamine 15.4.2.3. Growth Hormones 15.4.2.4. Others 15.4.3. Intestinal transplant surgery 15.4.4. Others 15.5. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.5.1. Infants / Children 15.5.2. Adults 15.6. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.6.1. Gastrointestinal Specialty Clinics 15.6.2. Hospitals 15.6.3. Others 15.7. Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 15.7.1. China 15.7.1.1. China Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.1.1.1. Diarrhea 15.7.1.1.2. Fatigue 15.7.1.1.3. Weight loss 15.7.1.1.4. Malnutrition 15.7.1.1.5. Others 15.7.1.2. China Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.1.2.1. Blood Tests 15.7.1.2.2. Computerized Tomography (CT) scan 15.7.1.2.3. Fecal fat tests 15.7.1.2.4. Upper Gastrointestinal (GI) Series 15.7.1.2.5. X-ray 15.7.1.2.6. Liver Biopsy 15.7.1.2.7. Others 15.7.1.3. China Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.1.3.1. Nutritional support 15.7.1.3.1.1. Oral rehydration 15.7.1.3.1.2. Parenteral nutrition. 15.7.1.3.1.3. Vitamin and mineral supplements 15.7.1.3.1.4. Special Diet 15.7.1.3.1.5. Others 15.7.1.3.2. Medications 15.7.1.3.2.1. GLP-2 15.7.1.3.2.2. Glutamine 15.7.1.3.2.3. Growth Hormones 15.7.1.3.2.4. Others 15.7.1.3.3. Intestinal transplant surgery 15.7.1.3.4. Others 15.7.1.4. China Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.1.4.1. Infants / Children 15.7.1.4.2. Adults 15.7.1.5. China Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.1.5.1. Gastrointestinal Specialty Clinics 15.7.1.5.2. Hospitals 15.7.1.5.3. Others 15.7.2. Japan 15.7.2.1. Japan Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.2.1.1. Diarrhea 15.7.2.1.2. Fatigue 15.7.2.1.3. Weight loss 15.7.2.1.4. Malnutrition 15.7.2.1.5. Others 15.7.2.2. Japan Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.2.2.1. Blood Tests 15.7.2.2.2. Computerized Tomography (CT) scan 15.7.2.2.3. Fecal fat tests 15.7.2.2.4. Upper Gastrointestinal (GI) Series 15.7.2.2.5. X-ray 15.7.2.2.6. Liver Biopsy 15.7.2.2.7. Others 15.7.2.3. Japan Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.2.3.1. Nutritional support 15.7.2.3.1.1. Oral rehydration 15.7.2.3.1.2. Parenteral nutrition. 15.7.2.3.1.3. Vitamin and mineral supplements 15.7.2.3.1.4. Special Diet 15.7.2.3.1.5. Others 15.7.2.3.2. Medications 15.7.2.3.2.1. GLP-2 15.7.2.3.2.2. Glutamine 15.7.2.3.2.3. Growth Hormones 15.7.2.3.2.4. Others 15.7.2.3.3. Intestinal transplant surgery 15.7.2.3.4. Others 15.7.2.4. Japan Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.2.4.1. Infants / Children 15.7.2.4.2. Adults 15.7.2.5. Japan Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.2.5.1. Gastrointestinal Specialty Clinics 15.7.2.5.2. Hospitals 15.7.2.5.3. Others 15.7.3. India 15.7.3.1. India Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.3.1.1. Diarrhea 15.7.3.1.2. Fatigue 15.7.3.1.3. Weight loss 15.7.3.1.4. Malnutrition 15.7.3.1.5. Others 15.7.3.2. India Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.3.2.1. Blood Tests 15.7.3.2.2. Computerized Tomography (CT) scan 15.7.3.2.3. Fecal fat tests 15.7.3.2.4. Upper Gastrointestinal (GI) Series 15.7.3.2.5. X-ray 15.7.3.2.6. Liver Biopsy 15.7.3.2.7. Others 15.7.3.3. India Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.3.3.1. Nutritional support 15.7.3.3.1.1. Oral rehydration 15.7.3.3.1.2. Parenteral nutrition. 15.7.3.3.1.3. Vitamin and mineral supplements 15.7.3.3.1.4. Special Diet 15.7.3.3.1.5. Others 15.7.3.3.2. Medications 15.7.3.3.2.1. GLP-2 15.7.3.3.2.2. Glutamine 15.7.3.3.2.3. Growth Hormones 15.7.3.3.2.4. Others 15.7.3.3.3. Intestinal transplant surgery 15.7.3.3.4. Others 15.7.3.4. India Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.3.4.1. Infants / Children 15.7.3.4.2. Adults 15.7.3.5. India Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.3.5.1. Gastrointestinal Specialty Clinics 15.7.3.5.2. Hospitals 15.7.3.5.3. Others 15.7.4. New Zealand 15.7.4.1. New Zealand Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.4.1.1. Diarrhea 15.7.4.1.2. Fatigue 15.7.4.1.3. Weight loss 15.7.4.1.4. Malnutrition 15.7.4.1.5. Others 15.7.4.2. New Zealand Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.4.2.1. Blood Tests 15.7.4.2.2. Computerized Tomography (CT) scan 15.7.4.2.3. Fecal fat tests 15.7.4.2.4. Upper Gastrointestinal (GI) Series 15.7.4.2.5. X-ray 15.7.4.2.6. Liver Biopsy 15.7.4.2.7. Others 15.7.4.3. New Zealand Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.4.3.1. Nutritional support 15.7.4.3.1.1. Oral rehydration 15.7.4.3.1.2. Parenteral nutrition. 15.7.4.3.1.3. Vitamin and mineral supplements 15.7.4.3.1.4. Special Diet 15.7.4.3.1.5. Others 15.7.4.3.2. Medications 15.7.4.3.2.1. GLP-2 15.7.4.3.2.2. Glutamine 15.7.4.3.2.3. Growth Hormones 15.7.4.3.2.4. Others 15.7.4.3.3. Intestinal transplant surgery 15.7.4.3.4. Others 15.7.4.4. New Zealand Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.4.4.1. Infants / Children 15.7.4.4.2. Adults 15.7.4.5. New Zealand Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.4.5.1. Gastrointestinal Specialty Clinics 15.7.4.5.2. Hospitals 15.7.4.5.3. Others 15.7.5. Australia 15.7.5.1. Australia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.5.1.1. Diarrhea 15.7.5.1.2. Fatigue 15.7.5.1.3. Weight loss 15.7.5.1.4. Malnutrition 15.7.5.1.5. Others 15.7.5.2. Australia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.5.2.1. Blood Tests 15.7.5.2.2. Computerized Tomography (CT) scan 15.7.5.2.3. Fecal fat tests 15.7.5.2.4. Upper Gastrointestinal (GI) Series 15.7.5.2.5. X-ray 15.7.5.2.6. Liver Biopsy 15.7.5.2.7. Others 15.7.5.3. Australia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.5.3.1. Nutritional support 15.7.5.3.1.1. Oral rehydration 15.7.5.3.1.2. Parenteral nutrition. 15.7.5.3.1.3. Vitamin and mineral supplements 15.7.5.3.1.4. Special Diet 15.7.5.3.1.5. Others 15.7.5.3.2. Medications 15.7.5.3.2.1. GLP-2 15.7.5.3.2.2. Glutamine 15.7.5.3.2.3. Growth Hormones 15.7.5.3.2.4. Others 15.7.5.3.3. Intestinal transplant surgery 15.7.5.3.4. Others 15.7.5.4. Australia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.5.4.1. Infants / Children 15.7.5.4.2. Adults 15.7.5.5. Australia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.5.5.1. Gastrointestinal Specialty Clinics 15.7.5.5.2. Hospitals 15.7.5.5.3. Others 15.7.6. South Korea 15.7.6.1. South Korea Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.6.1.1. Diarrhea 15.7.6.1.2. Fatigue 15.7.6.1.3. Weight loss 15.7.6.1.4. Malnutrition 15.7.6.1.5. Others 15.7.6.2. South Korea Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.6.2.1. Blood Tests 15.7.6.2.2. Computerized Tomography (CT) scan 15.7.6.2.3. Fecal fat tests 15.7.6.2.4. Upper Gastrointestinal (GI) Series 15.7.6.2.5. X-ray 15.7.6.2.6. Liver Biopsy 15.7.6.2.7. Others 15.7.6.3. South Korea Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.6.3.1. Nutritional support 15.7.6.3.1.1. Oral rehydration 15.7.6.3.1.2. Parenteral nutrition. 15.7.6.3.1.3. Vitamin and mineral supplements 15.7.6.3.1.4. Special Diet 15.7.6.3.1.5. Others 15.7.6.3.2. Medications 15.7.6.3.2.1. GLP-2 15.7.6.3.2.2. Glutamine 15.7.6.3.2.3. Growth Hormones 15.7.6.3.2.4. Others 15.7.6.3.3. Intestinal transplant surgery 15.7.6.3.4. Others 15.7.6.4. South Korea Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.6.4.1. Infants / Children 15.7.6.4.2. Adults 15.7.6.5. South Korea Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.6.5.1. Gastrointestinal Specialty Clinics 15.7.6.5.2. Hospitals 15.7.6.5.3. Others 15.7.7. Southeast Asia 15.7.7.1. Southeast Asia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.7.1.1. Diarrhea 15.7.7.1.2. Fatigue 15.7.7.1.3. Weight loss 15.7.7.1.4. Malnutrition 15.7.7.1.5. Others 15.7.7.2. Southeast Asia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.7.2.1. Blood Tests 15.7.7.2.2. Computerized Tomography (CT) scan 15.7.7.2.3. Fecal fat tests 15.7.7.2.4. Upper Gastrointestinal (GI) Series 15.7.7.2.5. X-ray 15.7.7.2.6. Liver Biopsy 15.7.7.2.7. Others 15.7.7.3. Southeast Asia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.7.3.1. Nutritional support 15.7.7.3.1.1. Oral rehydration 15.7.7.3.1.2. Parenteral nutrition. 15.7.7.3.1.3. Vitamin and mineral supplements 15.7.7.3.1.4. Special Diet 15.7.7.3.1.5. Others 15.7.7.3.2. Medications 15.7.7.3.2.1. GLP-2 15.7.7.3.2.2. Glutamine 15.7.7.3.2.3. Growth Hormones 15.7.7.3.2.4. Others 15.7.7.3.3. Intestinal transplant surgery 15.7.7.3.4. Others 15.7.7.4. Southeast Asia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.7.4.1. Infants / Children 15.7.7.4.2. Adults 15.7.7.5. Southeast Asia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.7.5.1. Gastrointestinal Specialty Clinics 15.7.7.5.2. Hospitals 15.7.7.5.3. Others 15.7.7.6. Southeast Asia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 15.7.7.6.1. Indonesia 15.7.7.6.2. Thailand 15.7.7.6.3. Malaysia 15.7.7.6.4. Singapore 15.7.7.6.5. Rest of Southeast Asia 15.7.8. Rest of Asia Pacific 15.7.8.1. Rest of Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 15.7.8.1.1. Diarrhea 15.7.8.1.2. Fatigue 15.7.8.1.3. Weight loss 15.7.8.1.4. Malnutrition 15.7.8.1.5. Others 15.7.8.2. Rest of Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 15.7.8.2.1. Blood Tests 15.7.8.2.2. Computerized Tomography (CT) scan 15.7.8.2.3. Fecal fat tests 15.7.8.2.4. Upper Gastrointestinal (GI) Series 15.7.8.2.5. X-ray 15.7.8.2.6. Liver Biopsy 15.7.8.2.7. Others 15.7.8.3. Rest of Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 15.7.8.3.1. Nutritional support 15.7.8.3.1.1. Oral rehydration 15.7.8.3.1.2. Parenteral nutrition. 15.7.8.3.1.3. Vitamin and mineral supplements 15.7.8.3.1.4. Special Diet 15.7.8.3.1.5. Others 15.7.8.3.2. Medications 15.7.8.3.2.1. GLP-2 15.7.8.3.2.2. Glutamine 15.7.8.3.2.3. Growth Hormones 15.7.8.3.2.4. Others 15.7.8.3.3. Intestinal transplant surgery 15.7.8.3.4. Others 15.7.8.4. Rest of Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 15.7.8.4.1. Infants / Children 15.7.8.4.2. Adults 15.7.8.5. Rest of Asia Pacific Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 15.7.8.5.1. Gastrointestinal Specialty Clinics 15.7.8.5.2. Hospitals 15.7.8.5.3. Others 15.8. Key Segment for Channeling Investments 15.8.1. By Country 15.8.2. By Indication 15.8.3. By Diagnosis 15.8.4. By Treatment 15.8.5. By Application 15.8.6. By End User 16. Middle East and Africa Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 16.1. Overview 16.1.1. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) 16.2. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.2.1. Diarrhea 16.2.2. Fatigue 16.2.3. Weight loss 16.2.4. Malnutrition 16.2.5. Others 16.3. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.3.1. Blood Tests 16.3.2. Computerized Tomography (CT) scan 16.3.3. Fecal fat tests 16.3.4. Upper Gastrointestinal (GI) Series 16.3.5. X-ray 16.3.6. Liver Biopsy 16.3.7. Others 16.4. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.4.1. Nutritional support 16.4.1.1. Oral rehydration 16.4.1.2. Parenteral nutrition. 16.4.1.3. Vitamin and mineral supplements 16.4.1.4. Special Diet 16.4.1.5. Others 16.4.2. Medications 16.4.2.1. GLP-2 16.4.2.2. Glutamine 16.4.2.3. Growth Hormones 16.4.2.4. Others 16.4.3. Intestinal transplant surgery 16.4.4. Others 16.5. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.5.1. Infants / Children 16.5.2. Adults 16.6. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.6.1. Gastrointestinal Specialty Clinics 16.6.2. Hospitals 16.6.3. Others 16.7. Middle East and Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 16.7.1. Saudi Arabia 16.7.1.1. Saudi Arabia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.7.1.1.1. Diarrhea 16.7.1.1.2. Fatigue 16.7.1.1.3. Weight loss 16.7.1.1.4. Malnutrition 16.7.1.1.5. Others 16.7.1.2. Saudi Arabia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.7.1.2.1. Blood Tests 16.7.1.2.2. Computerized Tomography (CT) scan 16.7.1.2.3. Fecal fat tests 16.7.1.2.4. Upper Gastrointestinal (GI) Series 16.7.1.2.5. X-ray 16.7.1.2.6. Liver Biopsy 16.7.1.2.7. Others 16.7.1.3. Saudi Arabia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.7.1.3.1. Nutritional support 16.7.1.3.1.1. Oral rehydration 16.7.1.3.1.2. Parenteral nutrition. 16.7.1.3.1.3. Vitamin and mineral supplements 16.7.1.3.1.4. Special Diet 16.7.1.3.1.5. Others 16.7.1.3.2. Medications 16.7.1.3.2.1. GLP-2 16.7.1.3.2.2. Glutamine 16.7.1.3.2.3. Growth Hormones 16.7.1.3.2.4. Others 16.7.1.3.3. Intestinal transplant surgery 16.7.1.3.4. Others 16.7.1.4. Saudi Arabia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.7.1.4.1. Infants / Children 16.7.1.4.2. Adults 16.7.1.5. Saudi Arabia Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.7.1.5.1. Gastrointestinal Specialty Clinics 16.7.1.5.2. Hospitals 16.7.1.5.3. Others 16.7.2. UAE 16.7.2.1. UAE Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.7.2.1.1. Diarrhea 16.7.2.1.2. Fatigue 16.7.2.1.3. Weight loss 16.7.2.1.4. Malnutrition 16.7.2.1.5. Others 16.7.2.2. UAE Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.7.2.2.1. Blood Tests 16.7.2.2.2. Computerized Tomography (CT) scan 16.7.2.2.3. Fecal fat tests 16.7.2.2.4. Upper Gastrointestinal (GI) Series 16.7.2.2.5. X-ray 16.7.2.2.6. Liver Biopsy 16.7.2.2.7. Others 16.7.2.3. UAE Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.7.2.3.1. Nutritional support 16.7.2.3.1.1. Oral rehydration 16.7.2.3.1.2. Parenteral nutrition. 16.7.2.3.1.3. Vitamin and mineral supplements 16.7.2.3.1.4. Special Diet 16.7.2.3.1.5. Others 16.7.2.3.2. Medications 16.7.2.3.2.1. GLP-2 16.7.2.3.2.2. Glutamine 16.7.2.3.2.3. Growth Hormones 16.7.2.3.2.4. Others 16.7.2.3.3. Intestinal transplant surgery 16.7.2.3.4. Others 16.7.2.4. UAE Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.7.2.4.1. Infants / Children 16.7.2.4.2. Adults 16.7.2.5. UAE Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.7.2.5.1. Gastrointestinal Specialty Clinics 16.7.2.5.2. Hospitals 16.7.2.5.3. Others 16.7.3. Egypt 16.7.3.1. Egypt Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.7.3.1.1. Diarrhea 16.7.3.1.2. Fatigue 16.7.3.1.3. Weight loss 16.7.3.1.4. Malnutrition 16.7.3.1.5. Others 16.7.3.2. Egypt Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.7.3.2.1. Blood Tests 16.7.3.2.2. Computerized Tomography (CT) scan 16.7.3.2.3. Fecal fat tests 16.7.3.2.4. Upper Gastrointestinal (GI) Series 16.7.3.2.5. X-ray 16.7.3.2.6. Liver Biopsy 16.7.3.2.7. Others 16.7.3.3. Egypt Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.7.3.3.1. Nutritional support 16.7.3.3.1.1. Oral rehydration 16.7.3.3.1.2. Parenteral nutrition. 16.7.3.3.1.3. Vitamin and mineral supplements 16.7.3.3.1.4. Special Diet 16.7.3.3.1.5. Others 16.7.3.3.2. Medications 16.7.3.3.2.1. GLP-2 16.7.3.3.2.2. Glutamine 16.7.3.3.2.3. Growth Hormones 16.7.3.3.2.4. Others 16.7.3.3.3. Intestinal transplant surgery 16.7.3.3.4. Others 16.7.3.4. Egypt Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.7.3.4.1. Infants / Children 16.7.3.4.2. Adults 16.7.3.5. Egypt Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.7.3.5.1. Gastrointestinal Specialty Clinics 16.7.3.5.2. Hospitals 16.7.3.5.3. Others 16.7.4. Kuwait 16.7.4.1. Kuwait Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.7.4.1.1. Diarrhea 16.7.4.1.2. Fatigue 16.7.4.1.3. Weight loss 16.7.4.1.4. Malnutrition 16.7.4.1.5. Others 16.7.4.2. Kuwait Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.7.4.2.1. Blood Tests 16.7.4.2.2. Computerized Tomography (CT) scan 16.7.4.2.3. Fecal fat tests 16.7.4.2.4. Upper Gastrointestinal (GI) Series 16.7.4.2.5. X-ray 16.7.4.2.6. Liver Biopsy 16.7.4.2.7. Others 16.7.4.3. Kuwait Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.7.4.3.1. Nutritional support 16.7.4.3.1.1. Oral rehydration 16.7.4.3.1.2. Parenteral nutrition. 16.7.4.3.1.3. Vitamin and mineral supplements 16.7.4.3.1.4. Special Diet 16.7.4.3.1.5. Others 16.7.4.3.2. Medications 16.7.4.3.2.1. GLP-2 16.7.4.3.2.2. Glutamine 16.7.4.3.2.3. Growth Hormones 16.7.4.3.2.4. Others 16.7.4.3.3. Intestinal transplant surgery 16.7.4.3.4. Others 16.7.4.4. Kuwait Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.7.4.4.1. Infants / Children 16.7.4.4.2. Adults 16.7.4.5. Kuwait Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.7.4.5.1. Gastrointestinal Specialty Clinics 16.7.4.5.2. Hospitals 16.7.4.5.3. Others 16.7.5. South Africa 16.7.5.1. South Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.7.5.1.1. Diarrhea 16.7.5.1.2. Fatigue 16.7.5.1.3. Weight loss 16.7.5.1.4. Malnutrition 16.7.5.1.5. Others 16.7.5.2. South Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.7.5.2.1. Blood Tests 16.7.5.2.2. Computerized Tomography (CT) scan 16.7.5.2.3. Fecal fat tests 16.7.5.2.4. Upper Gastrointestinal (GI) Series 16.7.5.2.5. X-ray 16.7.5.2.6. Liver Biopsy 16.7.5.2.7. Others 16.7.5.3. South Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.7.5.3.1. Nutritional support 16.7.5.3.1.1. Oral rehydration 16.7.5.3.1.2. Parenteral nutrition. 16.7.5.3.1.3. Vitamin and mineral supplements 16.7.5.3.1.4. Special Diet 16.7.5.3.1.5. Others 16.7.5.3.2. Medications 16.7.5.3.2.1. GLP-2 16.7.5.3.2.2. Glutamine 16.7.5.3.2.3. Growth Hormones 16.7.5.3.2.4. Others 16.7.5.3.3. Intestinal transplant surgery 16.7.5.3.4. Others 16.7.5.4. South Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.7.5.4.1. Infants / Children 16.7.5.4.2. Adults 16.7.5.5. South Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.7.5.5.1. Gastrointestinal Specialty Clinics 16.7.5.5.2. Hospitals 16.7.5.5.3. Others 16.7.6. Rest of Middle East & Africa 16.7.6.1. Rest of Middle East & Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 16.7.6.1.1. Diarrhea 16.7.6.1.2. Fatigue 16.7.6.1.3. Weight loss 16.7.6.1.4. Malnutrition 16.7.6.1.5. Others 16.7.6.2. Rest of Middle East & Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 16.7.6.2.1. Blood Tests 16.7.6.2.2. Computerized Tomography (CT) scan 16.7.6.2.3. Fecal fat tests 16.7.6.2.4. Upper Gastrointestinal (GI) Series 16.7.6.2.5. X-ray 16.7.6.2.6. Liver Biopsy 16.7.6.2.7. Others 16.7.6.3. Rest of Middle East & Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 16.7.6.3.1. Nutritional support 16.7.6.3.1.1. Oral rehydration 16.7.6.3.1.2. Parenteral nutrition. 16.7.6.3.1.3. Vitamin and mineral supplements 16.7.6.3.1.4. Special Diet 16.7.6.3.1.5. Others 16.7.6.3.2. Medications 16.7.6.3.2.1. GLP-2 16.7.6.3.2.2. Glutamine 16.7.6.3.2.3. Growth Hormones 16.7.6.3.2.4. Others 16.7.6.3.3. Intestinal transplant surgery 16.7.6.3.4. Others 16.7.6.4. Rest of Middle East & Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 16.7.6.4.1. Infants / Children 16.7.6.4.2. Adults 16.7.6.5. Rest of Middle East & Africa Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 16.7.6.5.1. Gastrointestinal Specialty Clinics 16.7.6.5.2. Hospitals 16.7.6.5.3. Others 16.8. Key Segment for Channeling Investments 16.8.1. By Country 16.8.2. By Indication 16.8.3. By Diagnosis 16.8.4. By Treatment 16.8.5. By Application 16.8.6. By End User 17. Latin America Short Bowel Syndrome Market Analysis and Forecasts, 2022 – 2030 17.1. Overview 17.1.1. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) 17.2. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 17.2.1. Diarrhea 17.2.2. Fatigue 17.2.3. Weight loss 17.2.4. Malnutrition 17.2.5. Others 17.3. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 17.3.1. Blood Tests 17.3.2. Computerized Tomography (CT) scan 17.3.3. Fecal fat tests 17.3.4. Upper Gastrointestinal (GI) Series 17.3.5. X-ray 17.3.6. Liver Biopsy 17.3.7. Others 17.4. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 17.4.1. Nutritional support 17.4.1.1. Oral rehydration 17.4.1.2. Parenteral nutrition. 17.4.1.3. Vitamin and mineral supplements 17.4.1.4. Special Diet 17.4.1.5. Others 17.4.2. Medications 17.4.2.1. GLP-2 17.4.2.2. Glutamine 17.4.2.3. Growth Hormones 17.4.2.4. Others 17.4.3. Intestinal transplant surgery 17.4.4. Others 17.5. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 17.5.1. Infants / Children 17.5.2. Adults 17.6. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 17.6.1. Gastrointestinal Specialty Clinics 17.6.2. Hospitals 17.6.3. Others 17.7. Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Country 17.7.1. Brazil 17.7.1.1. Brazil Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 17.7.1.1.1. Diarrhea 17.7.1.1.2. Fatigue 17.7.1.1.3. Weight loss 17.7.1.1.4. Malnutrition 17.7.1.1.5. Others 17.7.1.2. Brazil Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 17.7.1.2.1. Blood Tests 17.7.1.2.2. Computerized Tomography (CT) scan 17.7.1.2.3. Fecal fat tests 17.7.1.2.4. Upper Gastrointestinal (GI) Series 17.7.1.2.5. X-ray 17.7.1.2.6. Liver Biopsy 17.7.1.2.7. Others 17.7.1.3. Brazil Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 17.7.1.3.1. Nutritional support 17.7.1.3.1.1. Oral rehydration 17.7.1.3.1.2. Parenteral nutrition. 17.7.1.3.1.3. Vitamin and mineral supplements 17.7.1.3.1.4. Special Diet 17.7.1.3.1.5. Others 17.7.1.3.2. Medications 17.7.1.3.2.1. GLP-2 17.7.1.3.2.2. Glutamine 17.7.1.3.2.3. Growth Hormones 17.7.1.3.2.4. Others 17.7.1.3.3. Intestinal transplant surgery 17.7.1.3.4. Others 17.7.1.4. Brazil Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 17.7.1.4.1. Infants / Children 17.7.1.4.2. Adults 17.7.1.5. Brazil Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 17.7.1.5.1. Gastrointestinal Specialty Clinics 17.7.1.5.2. Hospitals 17.7.1.5.3. Others 17.7.2. Argentina 17.7.2.1. Argentina Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 17.7.2.1.1. Diarrhea 17.7.2.1.2. Fatigue 17.7.2.1.3. Weight loss 17.7.2.1.4. Malnutrition 17.7.2.1.5. Others 17.7.2.2. Argentina Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 17.7.2.2.1. Blood Tests 17.7.2.2.2. Computerized Tomography (CT) scan 17.7.2.2.3. Fecal fat tests 17.7.2.2.4. Upper Gastrointestinal (GI) Series 17.7.2.2.5. X-ray 17.7.2.2.6. Liver Biopsy 17.7.2.2.7. Others 17.7.2.3. Argentina Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 17.7.2.3.1. Nutritional support 17.7.2.3.1.1. Oral rehydration 17.7.2.3.1.2. Parenteral nutrition. 17.7.2.3.1.3. Vitamin and mineral supplements 17.7.2.3.1.4. Special Diet 17.7.2.3.1.5. Others 17.7.2.3.2. Medications 17.7.2.3.2.1. GLP-2 17.7.2.3.2.2. Glutamine 17.7.2.3.2.3. Growth Hormones 17.7.2.3.2.4. Others 17.7.2.3.3. Intestinal transplant surgery 17.7.2.3.4. Others 17.7.2.4. Argentina Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 17.7.2.4.1. Infants / Children 17.7.2.4.2. Adults 17.7.2.5. Argentina Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 17.7.2.5.1. Gastrointestinal Specialty Clinics 17.7.2.5.2. Hospitals 17.7.2.5.3. Others 17.7.3. Rest of Latin America 17.7.3.1. Rest of Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Indication 17.7.3.1.1. Diarrhea 17.7.3.1.2. Fatigue 17.7.3.1.3. Weight loss 17.7.3.1.4. Malnutrition 17.7.3.1.5. Others 17.7.3.2. Rest of Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Diagnosis 17.7.3.2.1. Blood Tests 17.7.3.2.2. Computerized Tomography (CT) scan 17.7.3.2.3. Fecal fat tests 17.7.3.2.4. Upper Gastrointestinal (GI) Series 17.7.3.2.5. X-ray 17.7.3.2.6. Liver Biopsy 17.7.3.2.7. Others 17.7.3.3. Rest of Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Treatment 17.7.3.3.1. Nutritional support 17.7.3.3.1.1. Oral rehydration 17.7.3.3.1.2. Parenteral nutrition. 17.7.3.3.1.3. Vitamin and mineral supplements 17.7.3.3.1.4. Special Diet 17.7.3.3.1.5. Others 17.7.3.3.2. Medications 17.7.3.3.2.1. GLP-2 17.7.3.3.2.2. Glutamine 17.7.3.3.2.3. Growth Hormones 17.7.3.3.2.4. Others 17.7.3.3.3. Intestinal transplant surgery 17.7.3.3.4. Others 17.7.3.4. Rest of Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By Application 17.7.3.4.1. Infants / Children 17.7.3.4.2. Adults 17.7.3.5. Rest of Latin America Short Bowel Syndrome Market Revenue (US$ Mn) and Forecasts, By End User 17.7.3.5.1. Gastrointestinal Specialty Clinics 17.7.3.5.2. Hospitals 17.7.3.5.3. Others 17.8. Key Segment for Channeling Investments 17.8.1. By Country 17.8.2. By Indication 17.8.3. By Diagnosis 17.8.4. By Treatment 17.8.5. By Application 17.8.6. By End User 18. Competitive Benchmarking 18.1. Brand Benchmarking 18.2. Market Share Analysis, 2021 18.3. Global Presence and Growth Strategies 18.3.1. Mergers and Acquisitions 18.3.2. Product Launches 18.3.3. Investments Trends 18.3.4. R&D Initiatives 19. Player Profiles 19.1. 9 Meters Biopharma, Inc. 19.1.1. Company Details 19.1.2. Company Overview 19.1.3. Product Offerings 19.1.4. Key Developments 19.1.5. Financial Analysis 19.1.6. SWOT Analysis 19.1.7. Business Strategies 19.2. Adis International Ltd 19.2.1. Company Details 19.2.2. Company Overview 19.2.3. Product Offerings 19.2.4. Key Developments 19.2.5. Financial Analysis 19.2.6. SWOT Analysis 19.2.7. Business Strategies 19.3. Ardelyx 19.3.1. Company Details 19.3.2. Company Overview 19.3.3. Product Offerings 19.3.4. Key Developments 19.3.5. Financial Analysis 19.3.6. SWOT Analysis 19.3.7. Business Strategies 19.4. Emmaus Medical, Inc. 19.4.1. Company Details 19.4.2. Company Overview 19.4.3. Product Offerings 19.4.4. Key Developments 19.4.5. Financial Analysis 19.4.6. SWOT Analysis 19.4.7. Business Strategies 19.5. Hanmi Pharm. Co. Ltd 19.5.1. Company Details 19.5.2. Company Overview 19.5.3. Product Offerings 19.5.4. Key Developments 19.5.5. Financial Analysis 19.5.6. SWOT Analysis 19.5.7. Business Strategies 19.6. OxThera 19.6.1. Company Details 19.6.2. Company Overview 19.6.3. Product Offerings 19.6.4. Key Developments 19.6.5. Financial Analysis 19.6.6. SWOT Analysis 19.6.7. Business Strategies 19.7. R&D Systems, Inc. 19.7.1. Company Details 19.7.2. Company Overview 19.7.3. Product Offerings 19.7.4. Key Developments 19.7.5. Financial Analysis 19.7.6. SWOT Analysis 19.7.7. Business Strategies 19.8. Takeda Pharmaceuticals, Inc. 19.8.1. Company Details 19.8.2. Company Overview 19.8.3. Product Offerings 19.8.4. Key Developments 19.8.5. Financial Analysis 19.8.6. SWOT Analysis 19.8.7. Business Strategies 19.9. VectivBio AG 19.9.1. Company Details 19.9.2. Company Overview 19.9.3. Product Offerings 19.9.4. Key Developments 19.9.5. Financial Analysis 19.9.6. SWOT Analysis 19.9.7. Business Strategies 19.10. Zealand Pharma A/S 19.10.1. Company Details 19.10.2. Company Overview 19.10.3. Product Offerings 19.10.4. Key Developments 19.10.5. Financial Analysis 19.10.6. SWOT Analysis 19.10.7. Business Strategies 19.11. Other Market Participants 20. Key Findings **Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.